AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study
Dow Jones
Yesterday
AbbVie said a drug to treat blood cancer met its dual primary endpoints in a phase 3 study.
The company said etentamig demonstrated a significantly higher objective response rate and improvements in progression-free survival over standard available therapies in patients with triple-class exposed relapsed/refractory multiple myeloma.
AbbVie said it plans to discuss the results with global regulatory authorities to determine next steps.
"These results underscore our confidence in etentamig and our broader multiple myeloma strategy, which explores complementary T-cell engagers, targeted small molecules and rational combinations designed to address distinct disease mechanisms and patient needs over time," said AbbVie's therapeutic area head, oncology, solid tumor and hematology, Daejin Abidoye.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.